Marshall Wace
IBRX icon

Marshall Wace’s ImmunityBio IBRX Stock Holding History

Marshall Wace’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
+151,000
New +$1.03M ﹤0.01% 2064

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace's IBRX Position: Q1 2026 in Review

Marshall Wace opened a new position in ImmunityBio (IBRX) in Q1 2026: 77,025 shares worth $591K. The stake represents ﹤0.01% of the portfolio and ranks #2374 among its holdings. This is a return to the name: Marshall Wace previously reported a position in IBRX as recently as Q3 2025.

Marshall Wace first reported a position in IBRX in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.48M in Q4 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Marshall Wace held 77,025 shares of ImmunityBio worth $591K as of Q1 2026.
  • ImmunityBio was a new Marshall Wace position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2374 holding.
  • Marshall Wace first reported a position in ImmunityBio in Q4 2021 and has held it in 8 quarters since.
  • Marshall Wace's ImmunityBio position peaked at $1.48M in Q4 2021.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.